Gut

Replication of protein associations is not external validation of a fixed mortality score

Diambra and colleagues1 integrated metabolic dysfunction-associated steatotic liver disease phenotypes with proteomics to derive a four-protein mortality score (PS4: FTCD, FABP1, ADGRG1 and GAST). We ...
Gut

From pressure to prognosis: establishing a common language for portal hypertension in advanced chronic liver disease

Risk stratification in compensated advanced chronic liver disease has traditionally been based on the identification of ...
gut.bmj

Repositioning dual GLP-1/GIP receptor agonists for the treatment of colitis and colitis-associated tumourigenesis

We read with great interest the commentary by Benson Massey, which raises concerns about the recent widespread use of glucagon-like peptide-1 (GLP-1) agonists.1 We offer an alternative perspective and ...
gut.bmj

SIRT6 promotes intrahepatic cholangiocarcinoma development by reprogramming glutamine metabolism via enhanced GLUL

Background SIRT6 acts as a tumour suppressor in multiple cancers by regulating glucose and lipid metabolism, but its role in intrahepatic cholangiocarcinoma (ICC) remains unclear. Objective We ...
gut.bmj

Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19

We read with great interest the article published by Zuo et al , which highlighted the presence of SARS-CoV-2 RNA in stool samples during active and convalescence phases of COVID-19 infection.1 ...
gut.bmj

Interleukin-11 drives human and mouse alcohol-related liver disease

2 Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore Objective Alcoholic hepatitis (AH) reflects acute exacerbation of alcoholic liver ...
gut.bmj

Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima

Objective The cross-immunogenicity of the recently approved infliximab-biosimilar Remsima (CT-P13) with the originator drug Remicade is still unknown. Design Sera of patients with IBD with or without ...
gut.bmj

The significance of haemochromatosis gene mutations in the general population: implications for screening

a Department of Medicine, b Department of Pathology, Christchurch Hospital, Christchurch, New Zealand Dr M J Burt, Department of Gastroenterology, Christchurch Hospital, Christchurch, New Zealand.
gut.bmj

Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps

1 Institute of Digestive Disease and Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China 2 Department of Surgery, ...
gut.bmj

Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics

a Department of Medicine, Cedars-Sinai Medical Center and the UCLA School of Medicine, Los Angeles, CA 90048, USA, b Department of Pediatrics, Cedars-Sinai Medical Center and the UCLA School of ...
gut.bmj

Revised British Society of Gastroenterology recommendation on the diagnosis and management of Barrett's oesophagus with low-grade dysplasia

Correspondence to Dr Massimiliano di Pietro, MRC Cancer Unit, University of Cambridge, Cambridge Biomedical Campus, P.O. Box 197, Cambridge CB2 0XZ, UK; md460{at}mrc-cu.cam.ac.uk The most recent ...
gut.bmj

YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition

Correspondence to Shumei Song, Departmental of GI Medical Oncology, U.T.MD. Anderson Cancer Center, Houston, TX 77030, USA; ssong{at}mdanderson.org; Jaffer A Ajani ...